Deutsche Numis Maintains Danaher(DHR.US) With Buy Rating, Maintains Target Price $270
Barclays Maintains Danaher(DHR.US) With Hold Rating, Raises Target Price to $285
TD Cowen Maintains Danaher(DHR.US) With Buy Rating, Raises Target Price to $310
Cantor Fitzgerald Maintains UnitedHealth(UNH.US) With Buy Rating, Maintains Target Price $591
UnitedHealth Group Analyst Ratings
Evercore ISI Adjusts Price Target on Danaher to $275 From $260, Maintains Outperform Rating
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $360
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $190
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Johnson & Johnson Analyst Ratings
Daiwa Downgrades Johnson & Johnson to Neutral From Outperform, Adjusts Price Target to $150 From $160
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Guggenheim Adjusts Johnson & Johnson's Price Target to $156 From $160, Maintains Neutral Rating
Merck & Co. Poised for Growth: Strong Q2 Performance and Promising Pipeline Fuel Buy Rating
Buy Rating on UnitedHealth Group: Proactive Management and Strong Growth Outlook
Analysts' Opinions Are Mixed on These Healthcare Stocks: Elevance Health (ELV), CVS Health (CVS) and Abbott Laboratories (ABT)
Buy Rating Affirmed for Johnson & Johnson on Strong Growth and Strategic Acquisitions
Johnson & Johnson Analyst Ratings
AbbVie Analyst Ratings